Celldex Therapeutics Inc
NASDAQ:CLDX
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
15.13
29.8
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Net Margin
Celldex Therapeutics Inc
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
|
Celldex Therapeutics Inc
NASDAQ:CLDX
|
1.8B USD |
-8 636%
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
-21 040%
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
394.7B USD |
4%
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
170.9B USD |
19%
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
149.5B USD |
28%
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
114.8B USD |
31%
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
-392%
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
78.1B USD |
32%
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
89.1B AUD |
19%
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
45.9B EUR |
43%
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
52.4B USD |
1%
|
Celldex Therapeutics Inc
Glance View
Celldex Therapeutics Inc. navigates the complex waters of biotechnology with a focus on creating innovative therapeutics that target debilitating diseases, particularly in oncology and immunotherapy. Rooted in scientific research and development, Celldex harnesses the power of the body's immune system to target and eradicate cancerous cells. The company operates by advancing a pipeline of drug candidates through rigorous clinical trials, each strategically developed to interrupt disease progression. Their approach often involves monoclonal antibodies, carefully engineered to specifically target tumor-associated antigens, thereby enhancing the body's immune response against malignancies. This concerted focus on precision medicine allows Celldex to continually push the boundaries of current medical treatments, marked by a commitment to pioneering in areas like breast cancer and glioblastoma. Celldex's revenue model pivots on the commercialization pathways of their drug candidates. They finance operations and fuel research through various channels, including equity offerings, strategic partnerships, and alliances with larger pharmaceutical entities. Licensing agreements further bolster the company's revenue, as they hold potential for milestone payments contingent on the successful advancement of drug candidates through clinical development stages. Additionally, Celldex may enter co-development arrangements that offer another revenue source and enable them to leverage external expertise and resources. This blend of ingenuity in drug development and astute financial strategies positions Celldex as a key player in the biotechnology landscape, steadily progressing in its mission to introduce groundbreaking treatments for serious diseases.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Celldex Therapeutics Inc's most recent financial statements, the company has Net Margin of -8 635.9%.